The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2015 | Targeting B-cell receptor signaling in lymphoid malignancies
Wyndham Wilson, MD, PhD from the National Cancer Institute, Bethesda, MD talks about the new developments in the fields of chronic lymphocytic leukemia (CLL), mantle cell lymphoma and large B-cell lymphoma. In particular, new drugs targeting B-cell receptor (BCR) signaling, such as ibrutinib (Brutton tyrosine kinase inhibitor), idelalisib (PI3K-delta inhibitor). Other diseases such as mantle cell lymphoma and activated B-cell (ABC) diffuse large B-cell lymphoma (DLBCL), have also been shown to be dependent of BCR signaling, indicating that patients can benefit from similar drugs.
